medline.ch Onkologie Urologische Tumoren

	Long-Term Oncological Outcomes of Active Surveillance for Low-Risk Prostate Cancer Diagnosed During the MRI Era. Fr J Urol Benheddi T, Seguier D, Puech P, Leroy X, Cailliau E, Behal H, Villers A, Olivier J. PMID: 39710329 [PubMed - as supplied by publisher]
	Association between pre-transplant actinic keratosis and skin cancer in kidney recipients: A retrospective cohort study. J Am Acad Dermatol Neubauer ZJK, Lipner SR. PMID: 39710110 [PubMed - as supplied by publisher]
	Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer. Discov Oncol Shen Q, Zhou K, Lu H, Zhang J, Xu Q, Zhang C, Yang C, Mao L. PMID: 39709589 [PubMed]
	Immunomonitoring in bladder cancer: a short report on stability of leukocytes and proteins in refrigerated urine samples. BMC Urol Sevko A, Prevosto C, Ragavan S, Domingos-Pereira S, Cesson V, Carrera MB, Derré L, Deban L. PMID: 39709428 [PubMed - indexed for MEDLINE]
	Relationship between circulating miRNA-222-3p and miRNA-136-5p and the efficacy of docetaxel chemotherapy in metastatic castration-resistant prostate cancer patients. BMC Urol Yuan S, Bi X, Shayiti F, Niu Y, Chen P. PMID: 39709424 [PubMed - indexed for MEDLINE]
	Navigating Management of Localized Prostate Cancer in the Geriatric Population. Crit Rev Oncol Hematol Malshy K, Golijanin B, Khaleel S, Danaher K, Widener J, Schmit S, Lagos G, Carniero B, Amin A, Cheng L, Pareek G, Mega A, Golijanin D, Hyams E. PMID: 39709068 [PubMed - as supplied by publisher]
	Comparative analysis of extracellular vesicles miRNAs (EV-miRNAs) and cell-free microRNAs (cf-miRNAs) reveals that EV-miRNAs are more promising as diagnostic and prognostic biomarkers for prostate cancer. Gene Nobrega M, Bisarro Dos Reis M, Ferreira de Souza M, Hugo Furini H, Costa Brandão Berti F, Larissa Melo Souza I, Mingorance Carvalho T, Zanata SM, Emilio Fuganti P, Malheiros D, Maria de Souza Fonseca Ribeiro E, Mara de Syllos Cólus I. PMID: 39708932 [PubMed - as supplied by publisher]
	The long-term survival outcome of sporadic bilateral renal cell carcinoma and optimization of surgical treatment: a large-scale population-based cohort study. Clin Exp Med Deng R, Qiu J, Shang J, Yu C, Tian P, Zhao Z, Cai L, Zhou J, Gong K. PMID: 39708253 [PubMed - indexed for MEDLINE]
	Impact of neurovascular bundle preservation on biochemical recurrence after robot-assisted radical prostatectomy for high-risk prostate cancer. World J Urol Hagimoto H, Kubota M, Matsui Y, Sumiyoshi T, Saito R, Segawa T, Fukuzawa S, Mitsumori K, Yoshida T, Akao T, Sekine Y, Negoro H, Kurahashi R, Shimatani K, Sawada A, Akamatsu S, Kobayashi T, Goto T, Dai-Cad TDCAD. PMID: 39708111 [PubMed - indexed for MEDLINE]
	The utility of modified RENAL nephrometry score in predicting the perioperative outcomes following open partial nephrectomy. Cell Mol Biol (Noisy-le-grand) Amin Said SH, Friad G, Sahib Jaafar M, Abdulhameed Arkawazi L, Fahad Raheem M, Aghaways I, Gubari MIM. PMID: 39707770 [PubMed - indexed for MEDLINE]
	The efficacy and safety of belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis. BMC Pharmacol Toxicol Song G, Xue S, Zhu Y, Wu C, Ji X. PMID: 39707485 [PubMed - indexed for MEDLINE]
	Is there a comparable Mp-MRI for incidental prostate uptake on 18Â F-FDG PET/CT? World J Surg Oncol , Kaya N, Savun M, Keskin ET, Yüzkan S, Arslan FZ, Budak B, Omak Ö, Yard, Özdemir H. PMID: 39707383 [PubMed - indexed for MEDLINE]
	Machine learning algorithms that predict the risk of prostate cancer based on metabolic syndrome and sociodemographic characteristics: a prospective cohort study. BMC Public Health Tran TT, Lee J, Kim J, Kim SY, Cho H, Kim J. PMID: 39707344 [PubMed - indexed for MEDLINE]
	Proteome-wide Mendelian randomization and therapeutic targets for bladder cancer. BMC Urol Wu MH, Zhang MH, Hu XD, Fan HX. PMID: 39707285 [PubMed - indexed for MEDLINE]
	Cancer awareness across borders: a comparative study of internet search trends for breast and prostate cancer in Europe and Turkey. BMC Cancer Kirli Bolukbas M, Figen M, Kocak Uzel E. PMID: 39707258 [PubMed - indexed for MEDLINE]
	Correction: Study on the Impact of Hormone Therapy for Prostate Cancer on the Quality of Life and the Psycho-Relational Sphere of Patients: ProQoL. Oncol Ther Cappuccio F, Buonerba C, Scafuri L, Di Trolio R, Dolce P, Trabucco SO, Erbetta F, Tulimieri E, Sciscio A, Ingenito C, Verde A, Di Lorenzo G. PMID: 39707035 [PubMed - as supplied by publisher]
	Avelumab + axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase 3 JAVELIN Renal 101 trial. Ann Oncol Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, Lee JL, Venugopal B, van den Eertwegh AJM, Negrier S, Gurney H, Albiges L, Berger R, Haanen JBAG, Oyervides Juárez V, Rini BI, Larkin J, Nolè F, Schmidinger M, Atkins MB, Tomita Y, Ellers-Lenz B, Hoffman J, Sandner R, Wang J, di Pietro A, Motzer RJ. PMID: 39706335 [PubMed - as supplied by publisher]
	First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective Study. J Natl Compr Canc Netw Xiong L, Shan X, Ma H, Guo S, Liu J, Chen X, Meng W, Guo B, Jiang L, Yan R, An X, Shi Y, Zhang Y, Xue T, Wei L, Xu D, Zhang Z, Qin Z, Yao K, Li Y, Spiess PE, Hu L, Xing N, Han H. PMID: 39705804 [PubMed - as supplied by publisher]
	Symptom Burden and Survivorship Care for Patients With Prostate Cancer on Androgen Deprivation Therapy. J Natl Compr Canc Netw Sentana-Lledo D, Saraf A, Morgans AK. PMID: 39705803 [PubMed - as supplied by publisher]
	Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States. JCO Clin Cancer Inform Doshi GK, Osterland AJ, Shi P, Yim A, Del Tejo V, Guttenplan SB, Eiffert S, Yin X, Rosenblatt L, Conkling PR. PMID: 39705641 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 164013

Seite 1 von 8201

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung